UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: informatics

Human Genomic Evidence: Revolutionising the identification and prioritisation of targets for better medicines

Nine out of 10 potential drugs that enter clinical trials never make it to the market. Failure often occurs because the biological target chosen is not well understood. However, it is hard to objectively select targets with a high chance of clinical success because the data required to predict efficacy and safety are complex, dispersed and incomplete. To address this challenge, Open Targets was founded in 2014 as a public-private partnership by GSK, EMBL-EBI and the Wellcome Sanger Institute. The consortium has grown since its launch, welcoming new partners Biogen in 2016, Takeda in 2017, and Celgene in 2018.

Read More

Analytics and Big Data in Pharma

Drug discovery and development is a complex process that requires integration of multiple data points, experiments and calculated risk/benefit assumptions. It is therefore only natural that virtualization and big data analytics are a natural fit for implementations, expected to demonstrate significant cost-effective gains for the betterment of society, providing access to effective and safe medications.

Read More

The Future of AI: A Q&A with Brandon Allgood

Brandon Allgood is the Chief Technology Officer at Numerate, as well as a co-founder. In addition to being responsible for the development of Numerate’s cloud-based machine learning platforms, Brandon runs the software & data science teams, and is the technical lead on all of the companies internal drug programs, as well as external collaborations.

Here, Brandon talks about what he thinks the future holds for AI and machine learning:

Read More

Big Data Analytics and Artificial Intelligence: 7 Design Principles to Empower Life Science Researchers

Life sciences research is increasingly relying on big data analytics to drive scientific discovery. One of the contributing factors to this trend is the fact that researchers are confronted with a rapidly growing body of scientific literature and databases required to interpret experimental outcomes.

Read More

Staying Ahead of Life Sciences Research and Implementation Trends in 2017 and Beyond

The traditional product pipeline, which information technology will compress and alter significantly in the life sciences in the coming years. Source: Wikimedia user MattBishop5 (CC BY-SA 3.0).

This article was originally published by Dassault Systèmes BIOVIA in October 2017, and is published here with permission.

Where can life science companies go operationally to maintain or create a competitive advantage? This question has been a constant in the industry since its inception, but recent advances in older technologies like Laboratory Information Management Systems (LIMS) and the appearance of promising newer technologies like the Internet of Things (IoT) have changed the nature of the answer. Which new technologies that are theoretically worthwhile have matured enough to be gracefully implemented operationally?

Read More

Reproducibility in Computational Biology

Recently Baker and Lithgow (Baker, 2016; Lithgow, et al., 2017) highlighted the problem of the reproducibility in research. Reproducibility criticality affects to different extent a large portion of the science fields (Baker, 2016). Bioinformatics is becoming a key element of many biological/medical studies (Searls, 2010) and reproducibility is also an important issue in this field (Kanwal, et al., 2017; Sandve, et al., 2013).

Read More

Big Data, Informatics and Pharma: An Open Letter From Vaibhav Narayan

Dear colleagues,

Therapeutic interventions have traditionally been developed for patients with established pathologies and overt clinical symptoms. Many diseases however, are not tractable in later stages and therefore therapies are needed that intervene earlier in the disease continuum.

Read More

Big data, knowing and AI: do they influence drug discovery?

The quest for magic bullets started with Paul Ehrlich. He wanted to target the syphilis bacteria without harming the patients, which led to Salvarsan. Ehrlich was a foundational thinker, and we owe him modern concepts such as receptor and pharmacophore. His impact on the field – seeking the ideal molecules – pervades drug discovery.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive